Month: August 2022

Stents

Racer CC

Post author By abhishek
Post date August 14, 2022

Racer CC

Sirolimus Eluting Coronary Stent System

Thin Structural Design Concomitating with Greater Deliverability

Ideal Strut Thickness

Racer CC is designed with thinner struts to provide the healing advantage associated with minimal vessel injury and better endothelialisation.

Greater Deliverability

Racer CC with its ideal strut thickness offers optimal strength, flexibility and pushability thus ensuring precise deployment

Enhanced Biocompatibility

The trusted stent platform of Racer CC has been steadily optimized with thinner struts and cell design offering better long-term outcomes

In this unique long term analysis at 10 years, Yukon has shown the lowest rate of Definite/ Probable Stent Thrombosis with a significant risk reduction than Cypher (50%) and numerically lower TLR rates as compared to Xience (29%) while maintaining the similar efficacy.

Comparison of clinical outcomes at 10 years in patients treated with new-generationBP-SES versus new-generation PP-EES versus early generation SES.

Technical Data

PRODUCT MATRIX / ORDERING INFORMATION*

COMPLIANCE CHART

Stents

Ultima PC #2

Post author By abhishek
Post date August 14, 2022

Ultima PC

Sirolinus Eluting Coronary Stent System

Ultimate Trackability for Treating Complexityy

Ideal Flexible Approach

Ultima PC offers new generation delivery system with ‘Flexi’ platform providing unmatched delivery in most tortuous vessels.

Enhanced Delivery System

The customized 2-Connector stent design of Ultima PC with thinner structural elements confirms for optimal deliverability.

Proprietary Hypotube

The new shaft design offers optimal force transfer with excellent push-ability and kink resistance allowing high manoeuvrability, justifying its use for the most tortuous vessels.

In this unique long term analysis at 10 years, Ultima PC has shown the lowest rate of Definite/ Probable Stent Thrombosis with a significant risk reduction than Cypher (50%) and numerically lower TLR rates as compared to Xience (29%) while maintaining the similar efficacy.

Comparison of clinical outcomes at 10 years in patients treated with new-generationBP-SES versus new-generation PP-EES versus early generation SES.

Technical Data

PRODUCT MATRIX / ORDERING INFORMATION*

COMPLIANCE CHART

Stents

Ultima PC

Post author By abhishek
Post date August 14, 2022

Ultima PC

Sirolinus Eluting Coronary Stent System

Ultimate Trackability for Treating Complexityy

Ideal Flexible Approach

Ultima PC offers new generation delivery system with ‘Flexi’ platform providing unmatched delivery in most tortuous vessels.

Enhanced Delivery System

The customized 2-Connector stent design of Ultima PC with thinner structural elements confirms for optimal deliverability.

Proprietary Hypotube

The new shaft design offers optimal force transfer with excellent push-ability and kink resistance allowing high manoeuvrability, justifying its use for the most tortuous vessels.

Comparison of clinical outcomes at 10 years in patients treated with new-generationBP-SES versus new-generation PP-EES versus early generation SES.

Technical Data

PRODUCT MATRIX / ORDERING INFORMATION*

COMPLIANCE CHART

Stents

Yukon Choice Flex

Post author By abhishek
Post date August 14, 2022

Yukon Choice Flex

Sirolinus Eluting Coronary Stent System

Advanced platform for redefining flexibility in tortuous anatomy

Ideal Flexible Approach

Yukon Choice Flex offers new generation delivery system with ‘Flexi’platform providing unmatched delivery in most tortuous vessels.

Enhanced Delivery System

The customized 2-Connector stent design of Yukon Choice Flex with thinner structural elements confirms for optimal deliverability.

Proprietary Hypotube

The new shaft design offers optimal force transfer with excellent push-ability and kink resistance allowing high manoeuvrability, justifying its use for the most tortuous vessels.

Unmatched Safety- In Complex Patients Subset

Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes: a pooled analysis of individual patient data from 3 randomised trials.

Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials

Technical Data

PRODUCT MATRIX / ORDERING INFORMATION

COMPLIANCE CHART

Stents

Yukon Choice PC

Post author By abhishek
Post date August 14, 2022

Yukon Choice PC

Sirolinus Eluting Coronary Stent System

New generation DES providing synergy of Biodegradable Polymer with microporous surface to enhance optimal performance

Less Polymeric Load Compared To Other DES

One million pores per cm² with an average depth of 2 µm ensures optimum drug release with minimal use of polymer

Top coat with Shellac Resin ensures better polymer- drug binding with negligible polymer flaking during stent expansion

Drug and polymer are co-released in 6-9 months leaving behind bare metal stent surface

Better Endothelialisation & Superior Strut Coverage

Drug polymer matrix coated only on the abluminal side using patented stent coating technology for drug release only to target tissue

No polymer on the luminal side ensures healthy endothelialisation and reduces the incidence of stent thrombosis

TECHNICAL DATA

PRODUCT MATRIX / ORDERING INFORMATION*

COMPLIANCE CHART

Stents

Yukon Choice PC Elite

Post author By abhishek
Post date August 14, 2022

Yukon Choice PC Elite

Sirolimus Eluting Coronary Stent System

The 1st DES to provide the synergy of Biodegradable Polymer with microporous surface protected with thermal insulation packing and electronic monitoring device for high quality and optimal performance

Setting New Standards of Quality Control

At temperatures beyond 8-25°C, Sirolimus develops oxidative degradation or Group-II impurities which may impact the potency of the drug.

To ensure protection from various environmental conditions, Yukon Choice PC Elite is equipped with Polystrene Thermal Insulation Packing.

The thermal insulated pack is further monitored by an electronic monitoring device Tag Alert manufactured by SENSITECH USA

Less Polymeric Load Compared to Other DES

Sirolimus:

It is a well-studied and clinically proven Immunosu

One million pores per cm² with average depth of 2 µm ensures optimum drug release with 1/4th of polymeric load as compared to other DES.

Top coat with Shellac Resin ensures better polymer drug binding with negligible polymer flaking during stent expansion.

ppressant. It inhibits activation of T cells and B cells by reducing their sensitivity to interleukin-2 (IL-2) through mammalian target of rapamycin inhibition (mTOR).

Stents

VIVO ISAR

Post author By abhishek
Post date August 14, 2022

VIVO ISAR

Polymer-Free Sirolimus Eluting Stent

Future Beyond Polymers

Polymers (Durable or Biocompatible) are an integral part of Drug Release Matrix in current generation DES as they ensure the Release Kinetics of the active drug, the critical determinant of antirestenotic efficacy. However, the mechanical properties of the Metallic Cage and Aggressive Inflammatory Reactions during polymer erosion are known to cause.

Persistent Fibrin Deposition

Delayed Endothelialisation

Chronic Inflammation

Persistent Platelet Activation

Current DES Polymers are often associated with Flaking, Webbing and Peeling which leads to impaired action of active drug.

VIVO ISAR is an innovative technology which eliminates the use of Polymer by using Dual Drug Technology: Sirolimus and Probucol

Sirolimus:

It is a well-studied and clinically proven Immunosuppressant. It inhibits activation of T cells and B cells by reducing their sensitivity to interleukin-2 (IL-2) through mammalian target of rapamycin inhibition (mTOR).

Probucol:

It is historically proven to impose anti-restenosis effects through anti-oxidative and direct anti-proliferative effects. Though in VIVO ISAR, it is not used as an Active Pharmaceutical Ingredient.

Probucol here mimics the role of a Polymer thus functioning as a drug carrier. Probucol is used as a Matrix-Builder for the controlled release of Sirolimus. Probucol binds the drug on the stent and its properties of being hydrophobic and anti-oxidative, facilitates a controlled and continuous drug release.

Stents